Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1952 1
1953 1
1955 2
1956 3
1958 2
1959 4
1960 2
1961 4
1962 4
1963 6
1964 4
1965 7
1966 9
1967 10
1968 30
1969 60
1970 134
1971 136
1972 164
1973 218
1974 280
1975 515
1976 613
1977 706
1978 811
1979 921
1980 1241
1981 1471
1982 1903
1983 2332
1984 2811
1985 3115
1986 3323
1987 3659
1988 4137
1989 4813
1990 5074
1991 5295
1992 5837
1993 6290
1994 6438
1995 7501
1996 8124
1997 8384
1998 8691
1999 8748
2000 8992
2001 9107
2002 9158
2003 9572
2004 10138
2005 10628
2006 11333
2007 11582
2008 12127
2009 11760
2010 11888
2011 12210
2012 12937
2013 12888
2014 13132
2015 13082
2016 12674
2017 12498
2018 12257
2019 11861
2020 12688
2021 12733
2022 11488
2023 11282
2024 12438
2025 15446
2026 14156
2027 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387,397 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.
Zong L, Zhang Z, Li X, Jia J, Jiang X, Wang Z, Liu W, Shen X, Feng X, Huang Y, Ding H, Song Y, Zheng Z, Yuan J, Li H. Zong L, et al. J Med Chem. 2025 Jul 24;68(14):14907-14918. doi: 10.1021/acs.jmedchem.5c01120. Epub 2025 Jul 3. J Med Chem. 2025. PMID: 40608546
Although the novel dual amylin and calcitonin receptor agonist (DACRA), petrelintide, is currently undergoing phase II clinical trials, its agonistic activity remains insufficient compared with natural agonists. Further optimization of the agonistic ca …
Although the novel dual amylin and calcitonin receptor agonist (DACRA), petrelintide, is currently undergoing phase II clinical trial …
Discovery of FXR/PPARgamma dual partial agonist.
Yamashita Y, Gohda K, Iguchi Y, Fujimori K, Oda K, Masuda A, Une M, Teno N. Yamashita Y, et al. Bioorg Med Chem. 2023 May 1;85:117238. doi: 10.1016/j.bmc.2023.117238. Epub 2023 Mar 24. Bioorg Med Chem. 2023. PMID: 37028120
Regarding recent agonist development, the partial agonists for FXR and PPARgamma are drawing attention from the standpoint of avoiding overactive responses caused by full agonists. ...To date, there are no published reports on FXR/PPARgamma dual partial ag …
Regarding recent agonist development, the partial agonists for FXR and PPARgamma are drawing attention from the standpoint of …
Deciphering the molecular pathways of saroglitazar: A dual PPAR alpha/gamma agonist for managing metabolic NAFLD.
Ezhilarasan D. Ezhilarasan D. Metabolism. 2024 Jun;155:155912. doi: 10.1016/j.metabol.2024.155912. Epub 2024 Apr 11. Metabolism. 2024. PMID: 38609038 Review.
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-alpha/gamma agonist, has been used to treat metabolic diseases such as insulin resistance and diabetic dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD). ...SARO inhibits in …
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-alpha/gamma agonist, has been used to treat metabolic d …
Search for new type of PPARgamma agonist-like anti-diabetic compounds from medicinal plants.
Matsuda H, Nakamura S, Yoshikawa M. Matsuda H, et al. Biol Pharm Bull. 2014;37(6):884-91. doi: 10.1248/bpb.b14-00037. Biol Pharm Bull. 2014. PMID: 24882400 Free article. Review.
Several constituents from medicinal plants were recently reported to show PPARgamma agonist-like activity in 3T3-L1 cells, but did not show agonistic activity at the receptor site different from thiazolidinediones. Our recent studies on PPARgamma agonist-like …
Several constituents from medicinal plants were recently reported to show PPARgamma agonist-like activity in 3T3-L1 cells, but did no …
Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor.
Akazawa H, Yasuda N, Komuro I. Akazawa H, et al. Mol Cell Endocrinol. 2009 Apr 29;302(2):140-7. doi: 10.1016/j.mce.2008.11.007. Epub 2008 Nov 18. Mol Cell Endocrinol. 2009. PMID: 19059460 Review.
Furthermore, mechanical stress can activate AT(1) receptor by inducing conformational switch without the involvement of AngII, and induce cardiac hypertrophy in vivo. These agonist-independent activities of AT(1) receptor can be inhibited by inverse agonists, but no …
Furthermore, mechanical stress can activate AT(1) receptor by inducing conformational switch without the involvement of AngII, and induce ca …
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.
Zhang J, Zhou L, Sun X, Lin Y, Yuan J, Yang C, Liao C. Zhang J, et al. Cancer Biol Ther. 2024 Dec 31;25(1):2426305. doi: 10.1080/15384047.2024.2426305. Epub 2024 Nov 14. Cancer Biol Ther. 2024. PMID: 39543823 Free PMC article.
SHR-1806 demonstrates a high affinity and specificity for human OX40 protein, eliciting FcgammaR-mediated agonistic effects, T cell activation, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities in vitro. ...Thus, SHR-180 …
SHR-1806 demonstrates a high affinity and specificity for human OX40 protein, eliciting FcgammaR-mediated agonistic effects, T cell a …
Structure-guided discovery of a single-domain antibody agonist against human apelin receptor.
Ma Y, Ding Y, Song X, Ma X, Li X, Zhang N, Song Y, Sun Y, Shen Y, Zhong W, Hu LA, Ma Y, Zhang MY. Ma Y, et al. Sci Adv. 2020 Jan 15;6(3):eaax7379. doi: 10.1126/sciadv.aax7379. eCollection 2020 Jan. Sci Adv. 2020. PMID: 31998837 Free PMC article.
Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. ...As revealed by the structure, JN241 binds to the extracellular side of APJ, makes critical contacts with the second ext …
Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chron …
Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates.
Udompholkul P, Baggio C, Gambini L, Sun Y, Zhao M, Hoffman RM, Pellecchia M. Udompholkul P, et al. Molecules. 2021 Jun 17;26(12):3687. doi: 10.3390/molecules26123687. Molecules. 2021. PMID: 34204178 Free PMC article.
This was expected given that the natural ephrin ligands also need to be dimerized or clustered to elicit agonistic activity in cell. In the present report we investigated whether the agonistic activity of 135H11 could be enhanced by biotin conjugation followed by co …
This was expected given that the natural ephrin ligands also need to be dimerized or clustered to elicit agonistic activity in cell. …
Discovery of Novel Selective Estrogen Receptor beta (SERbeta) Agonist (S)-STO021 as an Antiosteoporosis Candidate with Dual Functions of Inhibiting Osteoclastogenesis and Activating Osteoblastogenesis.
Peng C, Geng Z, Jiang Z, Ning JF, Wang N, Zhong C, Zhao Y, Sun X, Tang ML. Peng C, et al. J Med Chem. 2025 Nov 13;68(21):22715-22737. doi: 10.1021/acs.jmedchem.5c01697. Epub 2025 Oct 17. J Med Chem. 2025. PMID: 41105705
Recently, selective activation of estrogen receptor beta (SERbeta) was demonstrated to promote osteoblast formation and inhibit osteoclast absorption, suggesting that SERbeta agonists may be another promising therapeutic approach for treating osteoporosis. Herein, we repor …
Recently, selective activation of estrogen receptor beta (SERbeta) was demonstrated to promote osteoblast formation and inhibit osteoclast a …
ARB and cardioprotection.
Akazawa H, Yabumoto C, Yano M, Kudo-Sakamoto Y, Komuro I. Akazawa H, et al. Cardiovasc Drugs Ther. 2013 Apr;27(2):155-60. doi: 10.1007/s10557-012-6392-2. Cardiovasc Drugs Ther. 2013. PMID: 22538956 Review.
Experimental studies have demonstrated that Ang II-independent activation of AT1 receptor is profoundly relevant to the pathogenesis of cardiac remodeling in vivo, and that these agonist-independent activities of AT1 receptor can be inhibited by inverse agonists, bu …
Experimental studies have demonstrated that Ang II-independent activation of AT1 receptor is profoundly relevant to the pathogenesis of card …
387,397 results
You have reached the last available page of results. Please see the User Guide for more information.